Considerations for Second-Line and Higher Treatment of Recurrent mEC

Video

Drs Moore and O’Malley discuss the second-line and higher targeted treatment options that they’d consider for patients with mEC who develop recurrent disease on or after chemotherapy.

Transcript:

Kathleen Moore, MD: What would be your thought process for a patient in the recurrent setting who has mismatch repair-deficient disease? Or what other targeted approaches might you take in the recurrent setting based on biomarkers and other factors?

David O’Malley, MD: It’s great. I think if they’re deficient, with what’s available, pembrolizumab or dostarlimab, it’s brainless for me. If they’re proficient: lenvatinib, pembrolizumab. I think when you see these patients, treating them with the best therapies at that point. Again, in that patient recurrence, I send next-generation sequencing. I’m looking for targeted options for these patients. I do not retreat with carboplatin and paclitaxel. I think the data, I do not believe the platinum sensitive, platinum recurrence, we cannot extrapolate from ovarian cancer. If a patient’s been out 2, 3, 4 years, then maybe I would treat. But in that same instance, I can always go back to carboplatin-paclitaxel. Utilizing the immune therapy in that setting is absolutely what I would do even if it had been 1 or 2 years, getting that option on board and being able to go back to carboplatin-paclitaxel in the future.

Kathleen Moore, MD: I agree. It’s interesting now; when both you and I were younger there wasn’t any discussion of second-line treatment for endometrial cancer after the first metastatic setting because we had such ineffective treatments. Our best regimen…was weekly paclitaxel, with a response rate of about 15%, and then there was nothing. Our patients suffered for that lack of effective therapies. Now here we are with lenvatinib-pembrolizumab vs pembrolizumab or dostarlimab in the second-line setting. Maybe that will move to the front, but we have it in the second line right now. And now we have patients wondering what their third-line therapy is going to be, or their fourth-line therapy. So we are moving the needle a little in terms of being able to continuously treat patients. It’s not as robust as with ovarian cancer, where patients can get 5, 6, or 7 lines, but we are moving it out.

Transcript edited for clarity.

Related Videos
Video 4 - "Challenges in Adopting Targeted Therapies for BRAF Alterations"
Video 3 - "BRAF V600E Mutant Ganglioglioma"
Michael Leung, PharmD, an expert on colorectal cancer
A panel of 4 experts on colorectal cancer
Abdulrahman Sinno, MD
Video 4 - "The Evolving Treatment Landscape with CDK4/6 Inhibitors in Early HR+/HER2- Breast Cancer"
Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, experts on hepatocellular carcinoma
Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, experts on hepatocellular carcinoma
Video 2 - "Targeting RET Fusion in Brain Tumor"